Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213 Journal Article

  


Authors: Shimazaki, C.; Gulati, S. C.; Atzpodien, J.; Fried, J.; Colvin, O. M.; Clarkson, B. D.
Article Title: Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213
Abstract: To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and VP-16-213 (VP-16) as a purging agent for myeloma cells in bone marrow (BM) ex vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal BM cells were treated at different concentrations of 4-HC or VP-16. Clonogenic tumor cells from all three cell lines could be reduced by more than 4 logs, when treated alone or as a mixture with irradiated normal BM cells at a 4-HC concentration of 60 μM. Under similar conditions, approximately 1% of the normal BM myeloid progenitor granulocyte-macrophage colony-forming cells survived. These observations support the use of 4-HC for purging myeloma cells for autologous BM transplantation.
Keywords: human cell; multiple myeloma; etoposide; bone marrow transplantation; autologous bone marrow transplantation; bone marrow purging; 4 hydroperoxycyclophosphamide; human; priority journal; myeloma cell line
Journal Title: Acta Haematologica
Volume: 80
Issue: 1
ISSN: 0001-5792
Publisher: S. Karger AG  
Date Published: 1988-01-01
Start Page: 17
End Page: 22
Language: English
DOI: 10.1159/000205592
PUBMED: 3135688
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023749455&doi=10.1159%2f000205592&partnerID=40&md5=dd0dbf5b96a2d750a3eb6144507a4325
Notes: Article -- Export Date: 6 August 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Bayard Clarkson
    220 Clarkson
  2. Subhash C. Gulati
    129 Gulati
  3. Jens Atzodien
    24 Atzodien
Related MSK Work